Anti-inflammatory properties of the novel antitumor agent Yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2964-2971

  Allavena, Paola ^a,b   Signorelli, Mauro ^a,c   Chieppa, Marcello ^a   Erba, Eugenio ^b   Bianchi, Giancarlo ^a   Marchesi, Federica ^a   Olimpio, Chiara Omero ^a   Bonardi, Claudia ^c   Garbi, Annalisa ^c   Lissoni, Andrea ^c   De Braud, Filippo ^d   Jimeno, José ^f   D'Incalci, Maurizio ^b,e  

^a Dept of Immunology and Cell Biology ^*  (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e S Europe New Drugs Organization   (Italy)

^f PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLONY STIMULATING FACTOR 1; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; GROWTH FACTOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; TRABECTEDIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD CELL; CANCER PATIENT; CELL COUNT; CELL DIFFERENTIATION; CELL ISOLATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; DRUG INFUSION; DRUG SELECTIVITY; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INHIBITION KINETICS; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MEDIATOR; MEDIATOR RELEASE; MONOCYTE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; SIDE EFFECT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOKINES; DIOXOLES; HUMANS; ISOQUINOLINES; MACROPHAGES; MONOCYTES; TETRAHYDROISOQUINOLINES;

EID: 20144388299     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4037     Document Type: Article

References (50)

1. Guan Y, Sakai R, Rinehart KL, Wang AH. Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993;10:793-818.
2. Hendriks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999;10:1233-40.
3. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-11.
4. Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998;4:1977-83.
5. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-90.
6. D'Incalci M, Colombo T, Ubezio P, et al. The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003;39:1920-6.
7. Sessa C, De Braud F, Perotti A, et al. Trabectedin, ecteinascidin-743 (Yondelis) for women with ovarian carcinoma after failure of platinum-taxanes. J Clin Oncol. In press 2004.
8. Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia tarbinata. Biochemistry 1996;35:13303-9.
9. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
10. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105.
11. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8.
12. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
13. Marchini S, Marrazzo E, Bonomi R, et al. Molecular characterization of two human cancer cell lines selected in vitro for their chemotherapeutic resistance to ET743. Eur J Cancer 2005;41:323-33.
14. Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-4.
15. Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 2000;97:6775-9.
16. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-81.
17. Gordon S. The role of the macrophage in immune regulation. Res Immunol 1998;149:685-8.
18. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
19. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86.
20. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
21. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
22. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004;431:405-6.
23. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118:671-4.
24. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
25. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 1999;5:828-31.
26. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
27. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
28. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
29. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
30. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28:359-69.
31. Allavena P, Peccatori F, Maggioni D, et al. Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 1990;50:7318-23.
32. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004;64:8420-7.
33. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003;39:1842-51.
34. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002;50:309-19.
35. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein1 (MCP1) in human ovarian cancer. J Clin Invest 1995;95:2391-6.
36. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of CC chemokines. Am J Pathol 1997;150:1723-34.
37. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003;63:7451-61.
38. Mantovani A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 1994;71:5-16.
39. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001;70:478-90.
40. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
41. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000;6:3545-51.
42. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386-91.
43. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-25.
44. Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997;37:50-63.
45. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002;94:617-29.
46. Myokai F, Takashiba S, Lebo R, Amar S. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor α gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci U S A 1999;96:4518-23.
47. Lin SK, Kok SH, Yeh FT, et al. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Arthritis Rheum 2004;50:785-93.
48. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not EHK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003;278:2903-12.
49. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993;91:2194-206.
50. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase 11 study of etanercept (Enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004;10:6528-34.